Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Medpace Holdings Inc (MEDP) vs Nebius Group NV (NBIS) Price & Performance

Medpace Holdings IncTrade
Nebius Group NVTrade

Price performance (Past 24H)

Key statistics

Medpace Holdings Inc vs Nebius Group NV — how do they compare? Medpace Holdings Inc trades at $597.39 (market cap $16.90B), while Nebius Group NV trades at $254.39 (market cap $49.06B). The key difference: Nebius Group NV is far larger — about 2.9× Medpace Holdings Inc's market cap. Which is the better fit depends on your goals.

MEDPNBIS
Market Cap
$16.90B$49.06B
Sector
TechnologyTechnology
52-Week High
$620.59$286.69
52-Week Low
$393.42$64.06
Enterprise Value
$16.52B$49.26B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Medpace Holdings Inc

MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.

Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.

Nebius Group NV

NBIS trades at $259.20, up 40.79% in the last 24 hours, reflecting strong momentum following Q2 2026 earnings beats. The stock exhibits a bearish technical signal but maintains high analyst buy consensus (88.89%) with a consensus price target of $248.73. Recent news highlights robust AI cloud demand driving revenue growth, though negative EPS persists. Fundamentals show elevated valuation ratios (P/E 74.61, P/S 58.43) alongside impressive net income margin expansion to 93.09% in 2026 trends.

Outlook remains growth-focused with execution risks from capital-intensive expansion and short interest from notable investors like Michael Burry. The stock's premium valuation requires sustained high growth to justify current levels, while cash flow trends indicate significant investing outflows balanced by financing inflows. Competitive pressures in AI infrastructure and margin sustainability are key watchpoints.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP

About Nebius Group NV

Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.

Read more on NBIS